Fig. 2From: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancerThe analysis of mPFS in different post-osimertinib treatment groups. A The mPFS stratified by different post-osimertinib treatment. B Univariate COX regression analysis by baseline characteristics for mPFS. C Multivariate COX regression analysis by baseline characteristics for mPFSBack to article page